---
title: "CSPC Pharmaceutical: Buy Rating Reaffirmed as Earnings Visibility Improves and DCF-Based Target Price Raised to HK$13.44"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296645184.md"
description: "CMB International Securities analyst Jill Wu reaffirmed a Buy rating on CSPC Pharmaceutical, raising the DCF-based target price to HK$13.44. The upgrade reflects improved earnings visibility, recovering core product sales, and strong out-licensing potential. Morgan Stanley also maintained a Buy rating with an HK$11.00 target."
datetime: "2026-08-21T18:35:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296645184.md)
  - [en](https://longbridge.com/en/news/296645184.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296645184.md)
generator: "portal-rs"
---

# CSPC Pharmaceutical: Buy Rating Reaffirmed as Earnings Visibility Improves and DCF-Based Target Price Raised to HK$13.44

CMB International Securities analyst Jill Wu maintained a Buy rating on CSPC Pharmaceutical Group today and set a price target of HK$13.44.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Jill Wu has given his Buy rating due to a combination of factors that underscore both earnings visibility and long-term growth potential. She sees the domestic business having turned a corner, with core product sales recovering for several consecutive quarters, improving margins, and CNS drugs such as NBP gaining further traction through enhanced reimbursement and primary-care penetration.

In addition, Wu highlights a robust and scalable out-licensing engine that is already generating sizable upfront payments and should provide recurring, high-margin BD income as more assets are partnered globally. She also emphasizes CSPC’s rich late-stage pipeline, including multiple ADCs, bispecifics, and mRNA vaccines with numerous upcoming readouts, which together support her decision to maintain a Buy rating and to lift the DCF-based target price to HK$13.44.

In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a HK$11.00 price target.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer](https://longbridge.com/en/news/297024431.md)
- [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [UBS Sticks to Their Buy Rating for China Oilfield Services (CHOLF)](https://longbridge.com/en/news/297378308.md)
- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**